Petros G Nikolinakos

Petros G Nikolinakos

UNVERIFIED PROFILE

Are you Petros G Nikolinakos?   Register this Author

Register author
Petros G Nikolinakos

Petros G Nikolinakos

Publications by authors named "Petros G Nikolinakos"

Are you Petros G Nikolinakos?   Register this Author

6Publications

406Reads

14Profile Views

Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.

Lung Cancer 2015 Sep 29;89(3):357-9. Epub 2015 Jun 29.

Division of Hematology-Oncology, Department of Medicine, Chao Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA 92868, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2015.06.021DOI Listing
September 2015

PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer.

J Thorac Oncol 2015 Jan;10(1):134-42

*Department of Investigational Cancer therapeutics, University of Texas M. D. Anderson Cancer Center, Houston, Texas; †Global Diversity/Med Affairs, Eli Lilly and Company, Indianapolis, Indiana; ‡Medical Oncology, Tennessee Oncology, Nashville, Tennessee; §Hematology/Oncology, Florida Cancer Specialists, Fort Myers, Florida; •Medical Oncology, Highlands Oncology Group, Fayetteville, Arkansas; ¶Hematology-Medical Oncology, Oncology Heamatology Care Inc., Blue Ash, Ohio; #Hematology & Oncology, Internal Medicine, ACRC/Arizona Clinical Research Center, Arizona Oncology, Tucson, Arizona; **Hematology and Oncology, Michigan State University, East Lansing, Michigan; ††Northeast Georgia Cancer Care, University of Georgia Health Sciences University, Athens, Georgia; ‡‡Statistics Oncology, §§CDK4/6 Product Team, GPORWE-Oncology, ¶¶Oncology-Global Strategic Plan, ##Oncology-Early Phase, ***US Med Affairs and Late Phase Prod Dev, †††Global Medical Communications-Oncology, and ‡‡‡Global Med Affairs & Late Phase Prod Dev, Eli Lilly and Company, Indianapolis, Indiana; §§§Department of Medicine, Oncology Division, Washington University Medical School, St. Louis, Missouri; and ••Hematology/Oncology, Mayo Clinic Arizona, Scottsdale, Arizona.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000366DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4276572PMC
January 2015